Enveric Biosciences, Inc. ENVB
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Enveric Biosciences, Inc. (ENVB) is a healthcare company listed in the US with a market value of about $7M.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is future growth (0/5).
Key numbers: a 5-year average ROIC of -346%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 7% above the current price.
About Enveric Biosciences
Enveric Biosciences is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $36M in 2016 to $40M in 2019, growth of about 3.4% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 4067% over three years (dilution for shareholders).
Score: 1.0 / 5
Checks passed
- Price below intrinsic value (DCF, moderate assumptions)
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $40M | $43M | $49M | $36M |
| Net income | -$9M | -$10M | -$17M | -$18M | -$49M | -$7M | -$2M | -$17M | -$9M | -$3M |
| Free cash flow | — | — | -$14M | -$18M | -$12M | — | -$732191 | -$3M | -$3M | -$3M |
| EPS (diluted) | $-36.24 | $-228.48 | $-1455.49 | $-2340.01 | $-372.60 | $-214.20 | $-509.40 | $-3684.62 | $-3375.02 | $-945.00 |
| Net margin | — | — | — | — | — | — | -6.0% | -39.3% | -18.7% | -7.7% |
| ROIC | -165.9% | -477.7% | -664.2% | -172.2% | -249.5% | -129.9% | -54.0% | -1805.2% | -40.4% | -31.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Enveric Biosciences stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 7% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Enveric Biosciences pay a dividend?
Not currently.
Is Enveric Biosciences a good stock to buy?
We do not give buy or sell advice. Enveric Biosciences scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.